Seattle’s Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding firm, in a $225 million money deal announced immediately.
The transaction is predicted to shut in December.
Parse was co-founded in 2018 by Alex Rosenberg, who was a College of Washington postdoctoral fellow on the time, and Charles Roco, who was a UW graduate pupil. The corporate was an early entrant within the nascent subject of single-cell RNA sequencing.
Rosenberg and his colleagues found a brand new technique to profile RNAs whereas working within the lab of UW synthetic biology professor Georg Seelig. The enterprise initially launched as Cut up Biosciences, later altering its title and rising to 110 workers.
Parse raised greater than $50 million from buyers, together with a $41.5 million Collection B spherical announced in 2022.
Parse launched its first merchandise in 2021 and at present serves 3,000 clients in additional than 40 international locations. The corporate is predicted so as to add about $40 million in gross sales to Qiagen’s 2026 fiscal 12 months.
There’s an enormous vary of analysis questions that RNA profiling may also help reply. Understanding which RNAs are current in a cell provides scientists a read-out of lively genes. That helps distinguish totally different cell varieties, as an illustration in a blood pattern or a petri dish of stem cells turning into coronary heart cells.
Qiagen has developed applied sciences to isolate and analyze DNA, RNA and proteins from sources together with blood, tissue and different supplies. The corporate has about 5,700 workers in 35 places. It serves 500,000 clients globally.
The acquisition is topic to clearance below the U.S. Hart-Scott-Rodino Antitrust Enhancements Act and different circumstances.
